- Home
- NIE vs TNGX Comparison
NIE vs TNGX Comparison
Compare NIE & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NIE
- TNGX
- Stock Information
- Founded
- NIE 2007
- TNGX 2014
- Country
- NIE United States
- TNGX United States
- Employees
- NIE N/A
- TNGX N/A
- Industry
- NIE Investment Managers
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- NIE Finance
- TNGX Health Care
- Exchange
- NIE Nasdaq
- TNGX Nasdaq
- Market Cap
- NIE 676.4M
- TNGX 723.2M
- IPO Year
- NIE N/A
- TNGX N/A
- Fundamental
- Price
- NIE $24.95
- TNGX $6.71
- Analyst Decision
- NIE
- TNGX Strong Buy
- Analyst Count
- NIE 0
- TNGX 6
- Target Price
- NIE N/A
- TNGX $10.00
- AVG Volume (30 Days)
- NIE 70.5K
- TNGX 1.3M
- Earning Date
- NIE 01-01-0001
- TNGX 11-05-2025
- Dividend Yield
- NIE 9.04%
- TNGX N/A
- EPS Growth
- NIE N/A
- TNGX N/A
- EPS
- NIE N/A
- TNGX N/A
- Revenue
- NIE N/A
- TNGX $24,296,000.00
- Revenue This Year
- NIE N/A
- TNGX $6.56
- Revenue Next Year
- NIE N/A
- TNGX N/A
- P/E Ratio
- NIE N/A
- TNGX N/A
- Revenue Growth
- NIE N/A
- TNGX N/A
- 52 Week Low
- NIE $18.61
- TNGX $1.03
- 52 Week High
- NIE $22.47
- TNGX $10.85
- Technical
- Relative Strength Index (RSI)
- NIE 58.72
- TNGX 51.16
- Support Level
- NIE $24.53
- TNGX $6.25
- Resistance Level
- NIE $25.40
- TNGX $7.40
- Average True Range (ATR)
- NIE 0.19
- TNGX 0.39
- MACD
- NIE 0.02
- TNGX -0.05
- Stochastic Oscillator
- NIE 51.61
- TNGX 41.74
About NIE Virtus Equity & Convertible Income Fund of Beneficial Interest
Virtus AllianzGI Equity & Convertible Income Fund is a diversified, closed-end management investment company. The investment objective is to seek total return comprised of capital appreciation, current income, and gains. The fund pursues its objective by investing in a diversified portfolio of equity securities and income-producing convertible securities. Its portfolio of investments comprises different sector investments, such as aerospace and defense, banks, IT services, software, and others.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.